このページの翻訳は実験的なもので、現在開発中です。お待ちしております

TMC Life Sciences Berhad 将来の成長

Future 基準チェック /06

現在、 TMC Life Sciences Berhadの成長と収益を予測するのに十分なアナリストの調査がありません。

主要情報

n/a

収益成長率

n/a

EPS成長率

Healthcare 収益成長	2.4%
収益成長率	n/a
将来の株主資本利益率	n/a
アナリストカバレッジ	None
最終更新日	n/a

今後の成長に関する最新情報

更新なし

Recent updates

TMC Life Sciences Berhad (KLSE:TMCLIFE) Seems To Use Debt Quite Sensibly

Feb 14

We Think TMC Life Sciences Berhad (KLSE:TMCLIFE) Can Stay On Top Of Its Debt

Sep 29

Investors Met With Slowing Returns on Capital At TMC Life Sciences Berhad (KLSE:TMCLIFE)

Aug 26

TMC Life Sciences Berhad (KLSE:TMCLIFE) Shareholders Will Want The ROCE Trajectory To Continue

May 26

TMC Life Sciences Berhad's (KLSE:TMCLIFE) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

Feb 09

Returns On Capital - An Important Metric For TMC Life Sciences Berhad (KLSE:TMCLIFE)

Jan 13

Would Shareholders Who Purchased TMC Life Sciences Berhad's (KLSE:TMCLIFE) Stock Three Years Be Happy With The Share price Today?

Dec 22

Should You Use TMC Life Sciences Berhad's (KLSE:TMCLIFE) Statutory Earnings To Analyse It?

Dec 02

このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、TMC Life Sciences Berhad は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。

シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。

業績と収益の成長予測

KLSE:TMCLIFE - アナリストの将来予測と過去の財務データ ( )MYR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
6/30/2024	346	41	46	75	N/A
3/31/2024	357	53	65	100	N/A
12/31/2023	353	57	68	97	N/A
9/30/2023	332	48	41	73	N/A
6/30/2023	312	39	20	55	N/A
3/31/2023	298	49	3	52	N/A
12/31/2022	277	42	-11	45	N/A
9/30/2022	263	44	-18	52	N/A
6/30/2022	244	41	-33	36	N/A
3/31/2022	226	22	-47	-1	N/A
12/31/2021	213	18	-71	-1	N/A
9/30/2021	203	17	-87	-1	N/A
6/30/2021	201	20	-81	22	N/A
6/30/2020	184	16	-146	18	N/A
5/31/2020	190	10	-139	9	N/A
2/29/2020	206	22	-110	37	N/A
11/30/2019	200	22	-59	49	N/A
8/31/2019	195	21	-31	30	N/A
5/31/2019	187	33	-21	43	N/A
2/28/2019	180	30	-17	30	N/A
11/30/2018	174	29	-11	23	N/A
8/31/2018	169	28	-9	26	N/A
5/31/2018	165	28	N/A	16	N/A
2/28/2018	161	28	N/A	22	N/A
11/30/2017	157	28	N/A	14	N/A
8/31/2017	152	26	N/A	10	N/A
5/31/2017	146	21	N/A	4	N/A
2/28/2017	140	20	N/A	12	N/A
11/30/2016	136	19	N/A	16	N/A
8/31/2016	131	18	N/A	25	N/A
2/29/2016	121	13	N/A	14	N/A
11/30/2015	116	13	N/A	18	N/A
8/31/2015	107	10	N/A	10	N/A
5/31/2015	103	10	N/A	11	N/A
2/28/2015	98	9	N/A	16	N/A
11/30/2014	94	7	N/A	13	N/A
8/31/2014	91	8	N/A	12	N/A
5/31/2014	86	6	N/A	12	N/A
2/28/2014	82	5	N/A	11	N/A
11/30/2013	78	3	N/A	11	N/A

アナリストによる今後の成長予測

収入対貯蓄率: TMCLIFEの予測収益成長が貯蓄率 ( 3.6% ) を上回っているかどうかを判断するにはデータが不十分です。

収益対市場: TMCLIFEの収益がMY市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です

高成長収益: TMCLIFEの収益が今後 3 年間で大幅に増加すると予想されるかどうかを判断するにはデータが不十分です。

収益対市場: TMCLIFEの収益がMY市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: TMCLIFEの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: TMCLIFEの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

TMC Life Sciences Berhad 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Recent updates

New minor risk - Dividend sustainability

Dividend of RM0.022 announced

Full year 2024 earnings released: EPS: RM0.023 (vs RM0.023 in FY 2023)

TMC Life Sciences Berhad Proposes Special Single-Tier Dividend for the Financial Year Ended June 30, 2024, Payable on January 3, 2025

Third quarter 2024 earnings released: EPS: RM0.006 (vs RM0.008 in 3Q 2023)

Second quarter 2024 earnings released: EPS: RM0.008 (vs RM0.003 in 2Q 2023)

TMC Life Sciences Berhad Announces Redesignation of Dr Heng Jun Li Melvin from Non Executive Director to Group Chief Executive Officer

First quarter 2024 earnings released: EPS: RM0.009 (vs RM0.004 in 1Q 2023)

TMC Life Sciences Berhad Announces Redesignation of Kan Kheong Ng as Executive Vice Chairman

TMC Life Sciences Berhad, Annual General Meeting, Nov 02, 2023

TMC Life Sciences Berhad Announces Single-Tier Final Dividend Per Ordinary Share for the Financial Year Ended 30 June 2023, Payable on 03 January 2024

Full year 2023 earnings released: EPS: RM0.023 (vs RM0.024 in FY 2022)

High number of new directors

Tmc Life Sciences Berhad Announces Appointment of Dato' Mohd Sheridan Bin Ramli as Independent and Non Executive Director

TMC Life Sciences Berhad Announces Redesignation of Cheah Ho Chee as Independent and Non Executive Chairman of Risk Committee

Third quarter 2023 earnings released: EPS: RM0.008 (vs RM0.004 in 3Q 2022)

TMC Life Sciences Berhad Announces Appointment of Puan Mazrina Binti Arifin as Independent and Non Executive Director

TMC Life Sciences Berhad (KLSE:TMCLIFE) Seems To Use Debt Quite Sensibly

Second quarter 2023 earnings released: EPS: RM0.003 (vs RM0.004 in 2Q 2022)

TMC Life Sciences Berhad Appoints Dr. Heng Jun Li Melvin as Non Independent and Non Executive Director

TMC Life Sciences Berhad Reports Write Offs for the Quarter Ended September 30, 2022

First quarter 2023 earnings released: EPS: RM0.004 (vs RM0.002 in 1Q 2022)

TMC Life Sciences Berhad Announces Appointment of June Leong Lai Ling as Independent and Non Executive Member of Audit Committee

TMC Life Sciences Berhad, Annual General Meeting, Nov 03, 2022

We Think TMC Life Sciences Berhad (KLSE:TMCLIFE) Can Stay On Top Of Its Debt

Full year 2022 earnings released: EPS: RM0.024 (vs RM0.012 in FY 2021)

Investors Met With Slowing Returns on Capital At TMC Life Sciences Berhad (KLSE:TMCLIFE)

TMC Life Sciences Berhad Proposes Single-Tier Final Dividend for the Financial Year Ended 30 June 2022, Payable on 03 January 2023

TMC Life Sciences Berhad Appoints Cheah Ho Chee as Independent and Non Executive Director

TMC Life Sciences Berhad Announces CFO Changes

Third quarter 2022 earnings released: EPS: RM0.004 (vs RM0.002 in 3Q 2021)

Insufficient new directors

Insufficient new directors

Insufficient new directors

TMC Life Sciences Berhad Announces Re-Designation of Wong Yu Chee as Group Chief Accounting Officer from Group Chief Financial Officer

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Director Lee George Lam has joined 10th company board

Director Lee George Lam has joined 10th company board

Director Lee George Lam has joined 10th company board

Director Lee George Lam has joined 10th company board

Director Lee George Lam has joined 10th company board

Director Lee George Lam has joined 10th company board

Director Lee George Lam has joined 10th company board

Director Lee George Lam has joined 10th company board

Full year 2021 earnings released: EPS RM0.012 (vs RM0.009 in FY 2020)

TMC Life Sciences Berhad (KLSE:TMCLIFE) Shareholders Will Want The ROCE Trajectory To Continue

New 90-day high: RM0.79

TMC Life Sciences Berhad's (KLSE:TMCLIFE) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

New 90-day high: RM0.68

Returns On Capital - An Important Metric For TMC Life Sciences Berhad (KLSE:TMCLIFE)

TMC Life Sciences Berhad Announces Re-Designation of Dato' Sri Mohd Mokhtar Bin Mohd Shariff as Independent Non-Executive Chairman

New 90-day high: RM0.60

Would Shareholders Who Purchased TMC Life Sciences Berhad's (KLSE:TMCLIFE) Stock Three Years Be Happy With The Share price Today?

Should You Use TMC Life Sciences Berhad's (KLSE:TMCLIFE) Statutory Earnings To Analyse It?

New 90-day high: RM0.54

New 90-day low - RM0.48

Full year earnings released - EPS RM0.0091

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘